U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07310095) titled 'A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)' on Dec. 16.
Brief Summary: The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.
Study Start Date: Jan. 16, 2026
Study Type: INTERVENTIONAL
Condition:
Crohn Disease
Intervention:
DRUG: Guselkumab (GUS)
Guselkumab will be administered intravenously or by subcutaneous injection.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Xian-Janssen Pharmaceuti...